Product logins

Find logins to all Clarivate products below.


Mansoor Mukadam

Director, Commercial Strategy

Mansoor is a management consultant with 15 years of experience in Life sciences and Technology sector. Mansoor specializes in areas of Commercial strategy including Opportunity assessment, Geo-expansion and launch planning, M&A support, Forecasting, Tender planning and assessment. His experience spans across JAPAC, Middle East and Established markets.

Previously, Mansoor was an Associate Principal at IMS Consulting group, where he led various Commercial strategy projects in Geo-expansion, Go-to-Market planning, Commercial Due diligence, Policy strategy and Tender optimization. Mansoor also led engagements at PRTM and ZS Associates, where he advised several MNCs on Operations and Commercialization aspects such as Supply chain optimization, Manufacturing ad demand planning, CMC development, Go-to-market strategy, Customer Segmentation, Resource allocation and Goal setting. Besides consulting, Mansoor also held strategic roles in industry, where he managed Corporate strategy and M&A initiatives.

Throughout his career, Mansoor has developed a strong interest in product commercialization planning. He has actively engaged in thought leadership and developed whitepapers on key aspects of commercialization. Mansoor holds an MBA from the Indian School of Business, Hyderabad, and a B.Tech from National Institute of Technology, Trichy in India.


arrow_forward
Get in touch with Mansoor

Latest news

News August 6, 2026
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle London, U.K. — August 6, 2026— Clarivate…

News August 5, 2026
Clarivate Companies to Watch Report Spotlights Seven Innovators Shaping the Next Generation of Obesity Therapies

New report examines novel mechanisms and emerging approaches advancing obesity treatment beyond today’s GLP-1 therapies London, U.K., August 5, 2026 — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative…

News July 29, 2026
Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise ​LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.